Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Kansas City
    • School of Graduate Studies (UMKC)
    • Theses and Dissertations (UMKC)
    • Dissertations (UMKC)
    • 2018 Dissertations (UMKC)
    • 2018 UMKC Dissertations - Freely Available Online
    • View Item
    •   MOspace Home
    • University of Missouri-Kansas City
    • School of Graduate Studies (UMKC)
    • Theses and Dissertations (UMKC)
    • Dissertations (UMKC)
    • 2018 Dissertations (UMKC)
    • 2018 UMKC Dissertations - Freely Available Online
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Development of Targeted siRNA Therapeutics for Triple Negative Breast Cancer and Liver Fibrosis

    Zhao, Zhen
    View/Open
    [PDF] Development of Targeted siRNA Therapeutics for Triple Negative Breast Cancer and Liver Fibrosis (13.43Mb)
    Date
    2018
    Format
    Thesis
    Metadata
    [+] Show full item record
    Abstract
    The objective of this dissertation is to develop various systems to deliver small interfering RNA (siRNA) for the treatment of triple negative breast cancer (TNBC) and liver fibrosis. siRNAs targeting vascular endothelial growth factor (VEGF) and IκB kinase ε (IKBKE) were used for treating TNBC, while siRNA targeting poly(rC) binding protein 2 (PCBP2) was used for treating liver fibrosis. In Chapter 1, we briefly introduced the background about TNBC and liver fibrosis. We also presented the Statement of the Problems and Objectives. In Chapter 2, we reviewed the molecular mechanisms and potential treatments for TNBC and liver fibrosis. In Chapter 3, we developed a poly(ethyleneimine) (PEI) conjugated biodegradable multiblock polymer to form nanocomplexes with VEGF siRNA for TNBC treatment. The nanocomplex is able to deliver the VEGF siRNA into TNBC cells with a high transfection efficiency and low cytotoxicity. In vitro activity studies showed that the siRNA nanocomplexes significantly inhibit migration and invasion of TNBC cells. More importantly, the VEGF siRNA nanocomplex efficiently inhibit tumor growth in vivo and successfully downregulate VEGF expression in the tumor. These results suggested that VEGF siRNA is a promising anti-tumor agent for TNBC therapy, and the PEI 1800 conjugated bio-degradable multiblock polymer is a promising system to deliver siRNAs to TNBC cells. In Chapter 4, we developed a CD44-targeting, cholesterol modified cationic peptide nanocomplex to co-deliver IKBKE siRNA and cabazitaxel (CTX) for TNBC therapy. IKBKE siRNA significantly inhibits the proliferation, migration, and invasion of TNBC cells but has no apoptosis-inducing effect. In vivo studies also indicated that IKBKE siRNA can inhibit TNBC tumor growth. CD44-targeting CHA/CP/siRNA/CTX nanocomplex showed the synergistic effect of IKBKE siRNA and cabazitaxel on the inhibition of invasiveness and growth of TNBC tumors with an enhanced CD44 specific targeting effect. CHA/CP/siRNA/CTX nanocomplexes also exhibited a significant antitumor effect through IKBKE siRNA and cabazitaxel in vivo. Thus, IKBKE siRNA may be a promising anti-tumor agent for TNBC therapy, and co-delivery of IKBKE siRNA and cabazitaxel through a CD44-targeting nanocomplex is a potential strategy for TNBC treatment. Moreover, this multifunctional delivery system can also provide a good option for combined gene therapy and chemotherapy. In Chapter 5, we prepared three neutravidin-based siRNA nanocomplexes with different targeting ligands to deliver PCBP2 siRNA to hepatic stellate cells (HSCs). Insulin-like growth factor 2 receptor (IGF2R) is overexpressed in activated HSCs and therefore can be utilized for HSC-specific drug delivery. Compared to vitamin A and cholesterol, the IGF2R-specific peptide exhibited the highest targeting effect to human LX-2, rat HSC-T6 cell line, and activated primary rat HSCs. Accordingly, the IGF2Rspecific peptide coupled nanocomplex demonstrated higher silencing activity of PCBP2 and better inhibition on the migration of activated HSCs. The IGF2R-specific peptide coupled nanocomplex also showed the highest uptake in the liver and lowest uptake in the lung and kidney of the rats with CCl4-induced liver fibrosis.
    Table of Contents
    Introduction -- Literature review -- Development of a Polyethyleninine Conjugated Liner Multiblock Polymer to deliver VEGF siRNA for Triple Negative Breast Cancer -- Solencing IKBKE Gene with a Peptide-besed siRNA Nanocomplex Inhibits Invasiveness and Growth of Triple Negative Breast Cancer Cells -- Development of a Peptide-modified siRNA Nanocomplex for Hepatic Stellate Cells -- Summary and Conclusion -- Appendix
    URI
    https://hdl.handle.net/10355/79705
    Degree
    Ph.D. (Doctor of Philosophy)
    Thesis Department
    Pharmaceutical Sciences (UMKC)
     
    Chemistry (UMKC)
     
    Collections
    • Chemistry Electronic Theses and Dissertations (UMKC)
    • Pharmaceutical Sciences Electronic Theses and Dissertations (UMKC)
    • 2018 UMKC Dissertations - Freely Available Online

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems